Retatrutide

Fat LossInvestigational triple agonistEmerging

Lilly triple agonist (GIP, GLP-1, glucagon receptors). Phase 3 TRIUMPH program reported large weight-loss effects in 2025–2026; BLA planned around 2027. Not FDA-approved.

Calculate Dose

For research use only.

Key Facts

CAS: 2381089-83-2
Molecular Weight (MW): ~4731 g/mol
Half-life: ~6 days (weekly injection in trials)
Unit: mg
Administration Route: Subcutaneous
Frequency: Once weekly
Last updated: 8/23/2026
Targets: GIP receptorGLP-1 receptorGlucagon receptor

Overview

Lilly triple agonist (GIP, GLP-1, glucagon receptors). Phase 3 TRIUMPH program reported large weight-loss effects in 2025–2026; BLA planned around 2027. Not FDA-approved.

Protocol

Dosage Range: Trial titration commonly 2 mg weekly stepping toward 4–12 mg
Frequency: Once weekly
Cycle: Long-term trial setting
Administration Route: Subcutaneous
Reconstitution Guide: Varies

Science

Mechanism of Action

Single peptide that activates GIPR, GLP-1R, and GCGR to reduce appetite and increase energy expenditure. Phase 2 NEJM data and 2026 Phase 3 toplines support substantial weight reduction.